Ticker brief
RYTM
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
11
authors 14d
8
crowd 14d
+0.4σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-27 · now -0.25 (−1 bearish … +1 bullish)
Who spoke8
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | -0.45 | 4 | +0.01 |
| @VladBastion | B | -1.80 | 1 | +0.40 |
| @ShiftSeer | C | -1.36 | 1 | +0.00 |
| @BioStocks | C | -3.02 | 1 | +0.50 |
| @OzmosiHealth | C | · | 1 | +0.50 |
| @PrismMarketView | C | · | 1 | +0.50 |
| @BiopharmIQ | B | · | 1 | +0.50 |
| @PersimmonTI | A | -0.57 | 1 | +0.50 |
Recent signals11of 11 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-27 | @bioinvestor24 | -0.25 | Questions extreme therapy pricing while comparing costs and revenue burdens across several drug makers. | · | tweet ↗ |
| 2026-08-25 | @PersimmonTI | +0.50 | Japan approved named treatments from four biotech companies. | · | tweet ↗ |
| 2026-08-24 | @BiopharmIQ | +0.50 | Dense biotech list reports trial, PDUFA, filing and approval developments with market moves. | · | tweet ↗ |
| 2026-08-24 | @PrismMarketView | +0.50 | Reports Japanese approval of IMCIVREE and an expected year-end 2026 launch. | · | tweet ↗ |
| 2026-08-24 | @OzmosiHealth | +0.50 | Japan's health ministry approved Imcivree for acquired hypothalamic obesity. | · | tweet ↗ |
| 2026-08-24 | @BioStocks | +0.50 | Japan granted IMCIVREE marketing authorization, with commercial launch expected by year-end. | · | tweet ↗ |
| 2026-08-21 | @bioinvestor24 | +0.45 | Reports a third party's large SYRE stake, VKTX sale, RYTM addition and MRNA short. | · | tweet ↗ |
| 2026-08-19 | @bioinvestor24 | +0.10 | VKTX will be the next biotech play for generalist investors. — Forward-looking preference for VKTX as the next opportunity versus chasing RYTM. | · | tweet ↗ |
| 2026-08-18 | @bioinvestor24 | -0.25 | Mocks the GLP-1 antagonist valuation and questions pricing, durability, copying risk, and obesity-investor narratives. | · | tweet ↗ |
| 2026-08-17 | @ShiftSeer | +0.00 | Labels RYTM as a setup but all substantive detail is in unseen media | · | tweet ↗ |
| 2026-08-17 | @VladBastion | +0.40 | Presents five highly rated pharma growth stocks as a thematic basket. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.